Pasithea sets Sept. 17, 2026 expiry for KTTAW

Rhea-AI Filing Summary

Pasithea Therapeutics Corp. (KTTA) reports that its publicly traded warrants to purchase common stock, which trade on the Nasdaq Capital Market under the symbol KTTAW, will expire on September 17, 2026 in accordance with their terms under the Warrant Agency Agreement with VStock Transfer, LLC.

Any KTTAW warrants not exercised before that date will cease to be exercisable and have no further value. In connection with the expiration, KTTAW will cease trading on Nasdaq and the company will file Form 25 to delist and deregister the warrants, while its common stock will continue trading on Nasdaq under the symbol KTTA.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Key Figures

Warrant expiration date: September 17, 2026 Common stock par value: $0.0001 per share Warrant trading symbol: KTTAW +1 more

4 metrics

Warrant expiration date September 17, 2026 Expiration date for KTTAW warrants to purchase common stock

Common stock par value $0.0001 per share Par value of Pasithea Therapeutics common stock that KTTAW warrants relate to

Warrant trading symbol KTTAW Nasdaq Capital Market symbol for Pasithea Therapeutics’ warrants before expiration and delisting

Common stock trading symbol KTTA Nasdaq Capital Market symbol that will continue for Pasithea Therapeutics common stock

Key Terms

Warrant Agency Agreement, Notification of Removal from Listing and Registration, Form 25, Section 12(b) of the Securities Exchange Act of 1934, +1 more

5 terms

Warrant Agency Agreement financial

"in accordance with their terms as provided in the Warrant Agency Agreement between the Company"

Notification of Removal from Listing and Registration regulatory

"a Notification of Removal from Listing and Registration under Section 12(b) of the"

Form 25 regulatory

"on Form 25 will be filed with the Securities and Exchange Commission to delist the Warrants"

A Form 25 is an official filing with the U.S. Securities and Exchange Commission used to remove a company's stock or other security from a national exchange list. Investors should care because delisting often means less visibility, lower trading volume and wider price swings—similar to a product moving from a major supermarket to a small local market, which can make buying, selling and valuing the security more difficult.

Section 12(b) of the Securities Exchange Act of 1934 regulatory

"to delist the Warrants and deregister them under Section 12(b) of the Exchange Act"

warrants to purchase shares of Common Stock financial

"The warrants of Pasithea Therapeutics Corp. to purchase shares of the Company's common stock"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Pasithea Therapeutics (KTTA) announce about its KTTAW warrants?

Pasithea Therapeutics announced that its KTTAW warrants to purchase common stock will expire on September 17, 2026. Any warrants not exercised before expiration will no longer be exercisable and will have no value, and the warrants will be delisted from Nasdaq via a Form 25 filing.

When do Pasithea Therapeutics’ KTTAW warrants expire?

The KTTAW warrants of Pasithea Therapeutics expire on September 17, 2026. After that date, any unexercised warrants will cease to be exercisable and will be of no further value, and the warrants will be removed from listing and registration.

What happens to unexercised KTTAW warrants after September 17, 2026?

Any KTTAW warrants not exercised by September 17, 2026 will cease to be exercisable and will be of no further value. The warrants will also cease trading on Nasdaq, and Pasithea Therapeutics will file Form 25 to delist and deregister them.

Will Pasithea Therapeutics’ common stock KTTA remain listed after the KTTAW warrant expiration?

Yes. Pasithea Therapeutics states that its common stock, par value $0.0001 per share, will continue to trade on the Nasdaq Capital Market under the symbol KTTA after the KTTAW warrants expire and are delisted.

What regulatory filing will Pasithea Therapeutics use to delist KTTAW warrants?

Pasithea Therapeutics plans to file a Notification of Removal from Listing and Registration on Form 25 under Section 12(b) of the Exchange Act to delist the KTTAW warrants from Nasdaq and deregister them under the Exchange Act.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/16/2026 - 04:06 PM Accepted by SEC EDGAR 09/16/2026 - 04:06 PM Learn about SEC filing dates

false 0001841330 0001841330 2026-09-16 2026-09-16 0001841330 KTTA:CommonStockParValue0.0001PerShareMember 2026-09-16 2026-09-16 0001841330 KTTA:WarrantsToPurchaseSharesOfCommonStockParValue0.0001PerShareMember 2026-09-16 2026-09-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 16, 2026

Pasithea Therapeutics Corp. 

(Exact name of registrant as specified in its charter)

Delaware		001-40804		85-1591963
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

1111 Lincoln Road, Suite 500 Miami Beach, Florida		33139
(Address of principal executive offices)		(Zip Code)

(702) 514-4174

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		KTTA		The Nasdaq Capital Market
Warrants to purchase shares of Common Stock, par value $0.0001 per share		KTTAW		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

The warrants of Pasithea Therapeutics Corp. (the “Company”) to purchase shares of the Company's common stock, which trade on The Nasdaq Capital Market (“Nasdaq”) under the symbol “KTTAW” (the “Warrants”), will expire on September 17, 2026 in accordance with their terms as provided in the Warrant Agency Agreement between the Company and VStock Transfer, LLC, as warrant agent. Any Warrants not exercised prior to expiration will cease to be exercisable and will be of no further value.

In connection with the expiration, the Warrants will cease trading on Nasdaq, and a Notification of Removal from Listing and Registration under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), on Form 25 will be filed with the Securities and Exchange Commission to delist the Warrants and deregister them under Section 12(b) of the Exchange Act.

The Company's common stock, par value $0.0001 per share, will continue to trade on Nasdaq under the symbol “KTTA.”

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	PASITHEA THERAPEUTICS CORP.
Dated: September 16, 2026	By:	/s/ Tiago Reis Marques
		Name:	Tiago Reis Marques
		Title:	Chief Executive Officer

2

Filing Exhibits & Attachments

4 documents

Other Documents

• EX-101 XBRL SCHEMA FILE 3.7 KB
• EX-101 XBRL DEFINITION FILE 26.1 KB
• EX-101 XBRL LABEL FILE 36.0 KB
• EX-101 XBRL PRESENTATION FILE 24.7 KB